References
- Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of hallopeau: clinical perspectives. Psoriasis (Auckl). 2019;9:1–2. doi:10.2147/PTT.S180608.
- Chularojanamontri L, Rattanakorn K, Julanon N, et al. Acrodermatitis continua of Hallopeau and generalised pustular psoriasis: should they be the same or different entities? Exp Dermatol. 2023;32(8):1235–1245. doi:10.1111/exd.14805.
- Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021;11(6):1917–1929. doi:10.1007/s13555-021-00612-x.
- Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis. J Am Acad Dermatol. 2023; S0190-9622(23)03374-1. doi:10.1016/j.jaad.2023.11.060.
- Imafuku S, Okubo Y, Tada Y, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial. J Dermatol. 2024 Jan 24. doi:10.1111/1346-8138.17074.